Marin, J. (Julián)

Filtering

1995 - 199922000 - 20072

Settings

Author search.filters.isAuthorOfPublication.c7c3970f-c8e9-409d-b9fa-8289ce32f1ac

Search Results

Now showing 1 - 4 of 4
  • No Thumbnail Available
    The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience
    (Oxford University Press, 2007) Rodriguez, J. (José); Caballero, M.D. (M.D.); Albo, C. (Carmen); Marin, J. (Julián); Bendandi, M. (Maurizio); Arranz, R. (Reyes); Leon, A. (Angel); Conde, E. (Eulogio); Gutierrez, A. (Antonio)
    Abstract BACKGROUND: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas associated with poor prognosis with standard chemotherapy. Consolidation with autologous stem-cell transplantation (ASCT) may improve survival. We present 74 patients transplanted in first complete response (CR) from the Spanish Lymphoma and Autologous Transplantation Group cooperative group. PATIENTS AND METHODS: Median age was 46 years. Eighty-eight percent presented advanced (III-IV) Ann Arbor stage; 53% had B symptoms; 52% had high lactate dehydrogenase; 65% had two or three risk factors of the adjusted-International Prognostic Index; 58% presented a high Tumor score and in 14% more than two adverse factors of the Prognostic Index for peripheral T-cell lymphoma (PIT) were observed. RESULTS: With a median follow-up of 67 months from diagnosis, the 5-year overall survival (OS) was 68% and progression-free survival (PFS) reached 63%. The multivariate analysis showed that the only factor associated with a shorter OS and PFS was the presence of more than two risk factors from the PIT risk system. CONCLUSIONS: In a retrospective study with a prolonged follow-up, consolidation with ASCT in CR patients who had presented unfavorable prognostic factors at diagnosis substantially increased the OS and PFS when compared with conventional chemotherapy. The PIT risk system identified 14% of patients without benefit from ASCT consolidation. Thus, other innovative therapies are still necessary in certain cases.
  • Thumbnail Image
    A variant t(14;17) in acute promyelocytic leukemia. Positive response to retinoic acid treatment
    (Elsevier, 1995) Cigudosa, J.C. (Juan Cruz); Marin, J. (Julián); Bengoechea, E. (Enrique); Calasanz-Abinzano, M.J. (Maria Jose); Odero, M.D. (Maria Dolores); Gullon, A. (Arturo)
    We present a case of acute promyelocytic leukemia (APL) carrying an atypical translocation involving chromosomes 14 and 17. This translocation could be considered a variant of the APL-specific t(15;17). Positive response to retinoic acid treatment suggests molecular rearrangement of retinoic acid receptor alpha.
  • Thumbnail Image
    A recurrent translocation, t(3;11)(q21;q13), found in two distinct cases of acute myeloid leukemia
    (Elsevier, 1995) Cigudosa, J.C. (Juan Cruz); Marin, J. (Julián); Bengoechea, E. (Enrique); Calasanz-Abinzano, M.J. (Maria Jose); Odero, M.D. (Maria Dolores); Gullon, A. (Arturo)
    We report two cases of acute myeloid leukemia (M1 and M5B subtypes) with a similar translocation, t(3;11)(q21;q13). We discuss the involvement of these breakpoints in acute leukemia and their putative clinical implications.
  • No Thumbnail Available
    Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group
    (John Wiley and Sons, 2007) Rodriguez, J. (José); Caballero, M.D. (M.D.); Albo, C. (Carmen); Marin, J. (Julián); Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO); Bendandi, M. (Maurizio); Arranz, R. (Reyes); Leon, A. (Angel); Conde, E. (Eulogio); Gutierrez, A. (Antonio)
    OBJECTIVE: Retrospective data shows that peripheral T-cell lymphoma (PTCL) patients sensitive to conventional chemotherapy for aggressive lymphomas may respond better if this treatment is consolidated with frontline autologous stem cell transplantation (ASCT). Here, we present data from a prospective phase II trial of high-dose chemotherapy and ASCT as a frontline consolidation therapy for aggressive nodal PTCL. METHODS: This study involved 26 gallium-scan-positive patients with high-risk nodal PTCL [excluding anaplastic lymphoma kinase (ALK) positive]. Patients received three courses of MegaCHOP before they were evaluated, and those that were gallium-scan-negative at this stage then received another course of MegaCHOP and ASCT. Patients who remained gallium-scan-positive received two courses of an IFE regimen (ifosfamide 10 g/m(2), etoposide 150 mg/m(2)/12 h on days 1-3) and if they at least achieved PR, they then received the transplant. RESULTS: Complete response (CR) was achieved by 12 patients (46%) after three courses of MegaCHOP and 12 patients received IFE as a salvage therapy. After the ASCT (n = 19), 89% of patients achieved CR. In contrast, six patients (23%) did not receive the transplant because of the progression of the disease (n = 5) or lethal toxicity (n = 1). One patient in first-line CR refused ASCT. After a median follow-up of 35 months, the overall survival (OS) and progression-free survival (PFS) at 3 yr was 73% and 53%, respectively. Moreover, the OS, PFS and disease-free survival (DFS) were 84%, 56% and 63%, respectively 2 yr after transplant in patients who received ASCT consolidation (n = 19). CONCLUSIONS: Early salvage therapy for patients with high-risk aggressive nodal PTCL that do not achieve CR after three courses of chemotherapy and ASCT frontline consolidation for chemosensitive patients may improve treatment outcome.